SCHEMBL5653121

SCHEMBL5653121

CC(=Cc1ccccc1NC(=O)[C@H](CCCNC(=O)OCc1ccccc1)NC(=O)c1cc2ccccc2o1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 5/20 0.65
TAS1R3 Q7RTX0 2/20 0.42
TAS1R1 Q7RTX1 2/20 0.42
SIRT5 Q9NXA8 1/20 0.42
MAOB P27338 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC4 P56524 1/20 0.41
CPB1 P15086 1/20 0.41
CPB2 Q96IY4 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653118 1.00 PTGER4 (0.65) PTGER4TAS1R3TAS1R1SIRT5MAOB
SCHEMBL5652912 0.88 PTGER4 (0.66) PTGER4TAS1R3TAS1R1SIRT5MAOB
SCHEMBL5652909 0.88 PTGER4 (0.66) PTGER4TAS1R3TAS1R1SIRT5MAOB
SCHEMBL5653115 0.87 PTGER4 (0.64) PTGER4TAS1R3TAS1R1SIRT5MAOB
SCHEMBL5655093 0.86 PTGER4 (0.47) PTGER4TAS1R3TAS1R1SIRT5CA1
SCHEMBL5655087 0.86 PTGER4 (0.47) PTGER4TAS1R3TAS1R1SIRT5CA1
SCHEMBL5656210 0.84 PTGER4 (0.66) PTGER4HDAC1HDAC6
SCHEMBL5656217 0.84 PTGER4 (0.66) PTGER4HDAC1HDAC6
SCHEMBL5797231 0.84 PTGER4 (0.77) PTGER4SIRT5NPC1RAB9A
SCHEMBL5653761 0.82 PTGER4 (0.74) PTGER4SIRT5MAOBHDAC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists ASTELLAS PHARMA INC. (JP) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists PTGER4, OXER1, RXFP4 PTGER4 1/4885TAS1R3 2373/4885TAS1R1 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.